Disperazol
An antibiofilm approach that enhances the current arsenal of antibiotics against multi-drug resistant Gram-negative infections.
About Disperazol
Disperazol is developing compounds that dismantle biofilms of critical
Gram—negative pathogens.
Our proof-of-concept is Pseudomonas aeruginosa.
Leadership team
-
![Image of Prof Michael Givskov.]()
Prof Michael Givskov
Head of Science
-
![Image of Dr Michael Graz.]()
Dr Michael Graz
CEO
-
![Image of Assoc Prof Katrine Qvortrup.]()
Assoc Prof Katrine Qvortrup
Head of Chemistry
-
![Image of Prof MD Claus Moser.]()
Prof MD Claus Moser
Head of Clinical Science
Contact
Contact us to find out more or with any collaboration queries.
Dr Michael Graz
mgraz@disperazolpharma.com
+44 78 76 59 86 40
Prof Michael Givskov
mgivskov@sund.ku.dk
+45 21 40 98 67
13 years
In development
$500,000
Investment required to expand activity against further critical Gram-negative pathogens
3
Indications
